The PD-L1 expressing CTCs were first evaluated in breast cancer [16] and subsequently in cancers of the lungs [17,18], melanoma [19], head and neck squamous cell carcinoma [20], colon [21], prostate [21], and liver [22]. Here, CD274 is linked to melanoma.